DAVOS-ALZHEIMER’S-COLLAB
21.9.2021 15:02:15 CEST | Business Wire | Press release
The Davos Alzheimer’s Collaborative (DAC) is a global multi-stakeholder partnership that is mobilizing the world against Alzheimer’s disease. DAC announced today it has nearly completed financing of its foundational phase and has launched several key initiatives to advance Alzheimer’s research, prevention and care to advance the fight against the disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005348/en/
A recent WHO report shows that Alzheimer’s and dementia impacted more than 55 million families worldwide and cost the global economy approximately US$1.3 trillion in 2019. This annual cost is expected to rise to $2.8 trillion by 2030, based on predicted increases in cases and the cost of care. By averaging these numbers to assume an approximate annual cost of $2 trillion through 2030, we estimate the disease will cost the global economy a cumulative $20 trillion over the next decade.
Due to rapid gains in global life expectancy, more than 70% of Alzheimer’s cases will be in low- and middle-income countries (LMICs) by 2050, inhibiting their prospects for growth and exacerbating health and economic disparities between LMICs and higher-income countries. By contrast, nearly 80% of genomic analysis has come from people of European descent, even though more than 80% of the global population is not of European descent.
New advances in treatment have accelerated investment and innovation in the space, building momentum for change and increasing the urgency for healthcare systems to be prepared for major changes in how they care for patients with the disease in the coming years.
“Now is the time to act on Alzheimer’s. International bodies including the WHO, G7, and G20 have all made commitments in recent years that recognize the need to act together, act globally and act now to address this health crisis,” said George Vradenburg, Chair of DAC. “DAC is a response to these calls for action, bringing the speed and scale that has too often been lacking in previous efforts. The COVID-19 pandemic has shown us that a broad coalition of stakeholders working together can mobilize quickly to address a looming public health catastrophe. However, COVID-19 has also taught the world that we must have a robust preparedness plan – early and systematic testing and detection, timely access to real-world data, a standing, global, trial-ready system for developing and testing new therapies, and healthcare systems in high and low resource settings that are prepared to get the right intervention to the right patient at the right time. And, most importantly, we must include every nation and marshal every sector from the beginning to ensure a universal and equitable response.”
DAC is orchestrating an ambitious global effort to combat the Alzheimer’s crisis by linking, scaling and building on existing efforts across every sector. DAC is advancing this mission through several key initiatives, built on the scientific and business input of hundreds of experts in the space:
- Global Cohorts: Working with the International One Hundred K+ Cohorts Consortium (IHCC) and other partners, DAC is building a cohort of one million people who reflect the disease in all its global diversity, with data available to researchers everywhere in order to marshal the world’s scientific and industrial talent to find new clues to stopping Alzheimer’s. In our first six months of operations, we have linked 12 cohorts spanning Africa, Asia and South America, with more than 20 additional cohorts under consideration. We have stress-tested this diverse combined cohort using our Polygenic Risk Score (PRS) Feasibility Pilot, a first-of-its-kind, transethnic and transracial analysis of genetic data from approximately 100,000 people with Alzheimer’s.
- Clinical Trials: DAC is helping reduce the time and cost of clinical trials while improving their quality to accelerate the innovations that families and countries so desperately need. Working with the Global Alzheimer’s Platform, we are linking a network of 90 trial sites in North America with over a dozen European trial sites to accelerate key studies and implement novel trial designs, and we also are surveying site capacity across the rest of the world to extend future trials to other continents. We’re also designing a novel African clinical trial in Alzheimer’s disease and have secured a commitment from Roivant Social Ventures to make available an investigational new drug for use in this trial.
- Healthcare System Preparedness: DAC is investing in healthcare systems to produce new learnings using new technologies and protocols to improve the clinical care of people with, or at risk of, Alzheimer’s. To date, we have secured healthcare system partners in the U.S., Brazil, Mexico, Scotland, Japan and Jamaica to pilot the use of blood biomarkers and technology-enabled methods in clinical practice, including earlier detection of Alzheimer’s disease. We also held our first “Learning Laboratory” of these flagship health systems to share their innovative practices with approximately 200 attendees from health systems and national health ministries, including representatives of seven governments from around the world. The World Health Organization has agreed to serve as a technical advisor on these efforts.
“Alzheimer’s disease recognizes no boundaries. Yet too often our response is fragmented — leaving patients, families and researchers to face this burden alone, especially in low- and middle-income countries,” said Dr. Margaret Chan, Emeritus WHO Director General and Founding Dean of the Tsinghua Vanke School of Public Health . “The work of the Davos Alzheimer’s Collaborative, and its commitment to lead a new fight through new public-private partnerships, will help save countless lives and trillions of dollars lost to Alzheimer’s each year.”
Business Updates
In addition to these initiatives, DAC has achieved several business milestones that will lay the foundation for our continued work to eliminate the burden of Alzheimer’s.
DAC is now headquartered in Switzerland, with IRS 501c3 affiliate status in the U.S. We are also completing our foundational phase fund-raise with $25 million in commitments to advance our projects, in addition to invaluable contributions of time and talent, from supporters including Eli Lilly & Company, Roche, Biogen, Eisai, Otsuka, C2N, Cognivue, Linus Health and Cogstate.
“The progress made by the Davos Alzheimer’s Collaborative since its launch in January signals the urgent need for a collective global response to the growing public health crises of Alzheimer’s disease,” said Klaus Schwab, Founder and Executive Chairman of the World Economic Forum . “Following in the footsteps of initiatives incubated at the World Economic Forum, such as the Global Alliance for Vaccines and Immunization (GAVI) and the Coalition for Epidemic Preparedness Innovations (CEPI), the Davos Alzheimer’s Collaborative is bringing new cooperative energy and global vision to the fight against this disease that brings suffering to hundreds of millions of people, families and caregivers around the world.”
DAC’s founding Board members will guide the collaborative toward its 2022 priorities and beyond. A full list of DAC leadership group members is available here .
“DAC is bringing together the best minds to improve the speed and scale of the scientific fight against Alzheimer’s,” said Elias Zerhouni, Professor Emeritus, Johns Hopkins University; Former Director, National Institutes of Health and Former President of R&D, Sanofi. “We’ve built a plan of action informed by experts in Alzheimer’s disease, data science and digital technologies, and we are pleased to start executing it through these initiatives.”
DAC intends to announce further progress toward these goals during the Lausanne VIII Workshop in November 2021 and the World Economic Forum annual meeting in January 2022.
About the Davos Alzheimer’s Collaborative
Launched at the World Economic Forum’s 2021 meeting on The Davos Agenda, The Davos Alzheimer’s Collaborative is a multi-stakeholder partnership committed to aligning stakeholders with a new vision for our collective global response against the challenges Alzheimer’s presents to patients, caregivers and healthcare infrastructures. Convened by The World Economic Forum and The Global CEO Initiative on Alzheimer’s Disease (CEOi) and fueled by a mission of service to the estimated 150 million families and half a billion people inevitably impacted by this disease by 2050, DAC is a collaborative for the benefit of all people, in all places.
Note to Editors
Additional quotes from DAC’s leadership and partners are attached.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005348/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 15:45:00 CET | Press release
We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live
Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 15:39:00 CET | Press release
Two new AI capabilities, available now. Visual Intelligence turns camera footage into production data. Factbird MCP gives AI assistants direct access to production data in Factbird. Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real c
Argenta and Loyal Announce Partnership to Advance LOY-003, Loyal's Lifespan-Extension Candidate for Large-Breed Dogs16.11.2026 15:17:00 CET | Press release
Collaboration brings together Argenta's Molecule to Market capabilities and Loyal’s lifespan extension therapeutics with early development of LOY-003 Argenta, the global contract development, research and manufacturing organization (CDRMO) dedicated exclusively to animal health, and Loyal, the clinical-stage animal health company pioneering the first lifespan extension drugs for dogs, today announced a strategic partnership under which Argenta will support early-stage development of LOY-003, Loyal's investigational candidate for large-breed dog lifespan extension. The collaboration will focus on early development of the drug, with the potential to expand as the program advances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116891949/en/ Founded by CEO Celine Halioua, Loyal is working to bring the first FDA-approved lifespan extension drugs to market for dogs. The company's pipeline includes three investigational candida
NIKE, Inc. Unveils the Next Generation of Innovation Across Performance Sports and Sportswear16.11.2026 15:08:00 CET | Press release
From the next evolution of Nike Air to new Nike Mind and Nike Free footwear, Nike is solving distinct athlete needs — and creating platforms that can bring those breakthroughs to more athletes.New innovations and platforms span running, training, basketball, football and outdoor sports, reflecting Nike's focus on delivering best-in-class performance to athletes across disciplines.Nike is bringing performance innovation into everyday style, reinventing the classics athletes love while introducing new silhouettes, including Project Ride and Nike Morpho X.Much of what Nike is showing arrives over the coming year, with some innovations following later. Watch for more details in the months to come. NIKE, Inc. (NYSE: NKE) is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. This press release features multimedia. View the full release here: https://www.businesswire.com
2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 13:00:00 CET | Press release
The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
